KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Equity Ratio (2018 - 2025)

Vir Biotechnology's Equity Ratio history spans 8 years, with the latest figure at 0.76 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 7.21% year-over-year to 0.76; the TTM value through Dec 2025 reached 0.76, down 7.21%, while the annual FY2025 figure was 0.76, 7.21% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.76 at Vir Biotechnology, down from 0.78 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.86 in Q1 2024 and bottomed at 0.57 in Q1 2021.
  • The 5-year median for Equity Ratio is 0.79 (2025), against an average of 0.77.
  • The largest annual shift saw Equity Ratio dropped 28.09% in 2021 before it rose 20.91% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.73 in 2021, then rose by 1.21% to 0.74 in 2022, then rose by 11.74% to 0.83 in 2023, then fell by 0.75% to 0.82 in 2024, then decreased by 7.21% to 0.76 in 2025.
  • Per Business Quant, the three most recent readings for VIR's Equity Ratio are 0.76 (Q4 2025), 0.78 (Q3 2025), and 0.79 (Q2 2025).